Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present RXI Pharmaceuticals Corporation (OTC: RXII).

Full DD Report for RXII

You must become a subscriber to view this report.


Recent News from (OTC: RXII)

Blog Exposure - RXi Pharma and Iovance Biotherapeutics Announce Research Collaboration
LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on RXi Pharma Corp. (NASDAQ: RXII ), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RXII as the Company's latest news hit the wire. On...
Source: ACCESSWIRE IA
Date: May, 15 2018 07:10
RXI Pharmaceuticals' (RXII) CEO Geert Cauwenbergh on Q1 2018 Results - Earnings Call Transcript
RXI Pharmaceuticals Corporation (RXII) Q1 2018 Earnings Conference Call May 10, 2018 16:30 ET Executives Tamara McGrillen - Head, Investor Relations Geert Cauwenbergh - President and Chief Executive Officer Gerrit Dispersyn - Chief Development Officer Caitlin Kontulis - Princip...
Source: SeekingAlpha
Date: May, 12 2018 23:28
Premarket Gainers as of 9:05 am (05/11/2018)
MOSY +47%  on Q1 result . More news on: MoSys, Inc., Amira Nature Foods, The Trade Desk, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 11 2018 09:19
RXi Pharmaceuticals inks deal with Iovance Biotherapeutics to study its RNAi technology for the advancement of immuno-oncology therapeutics
RXi Pharmaceuticals (NASDAQ: RXII ) has entered into a research collaboration with Iovance Biotherapeutics to evaluate the potential synergies with RXi's sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs) for the use in the t...
Source: SeekingAlpha
Date: May, 11 2018 07:41
RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors
MARLBOROUGH, Mass. , May 11, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) announced today that it has entered into a research collaboration with Iovance Biotherapeutics to evaluate the potential synergies with RXi's novel sd-rxRNA therapeutic compounds and Iovanc...
Source: PR Newswire
Date: May, 11 2018 07:05
RXi Pharmaceuticals reports Q1 results
RXi Pharmaceuticals (NASDAQ: RXII ): Q1 EPS of -$0.90 More news on: RXI Pharmaceuticals Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 10 2018 07:16
RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
MARLBOROUGH, Mass. , May 10, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today reported i...
Source: PR Newswire
Date: May, 10 2018 07:05
RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO
MARLBOROUGH, Mass. , May 8, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced tod...
Source: PR Newswire
Date: May, 08 2018 14:20
RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference
MARLBOROUGH, Mass. , May 1, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today...
Source: PR Newswire
Date: May, 01 2018 07:05
Blog Exposure - Codexis Entered into Strategic Collaboration with Porton Pharma Solutions
Stock Monitor: RXi Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Codexis, Inc. (NASDAQ: CDXS ). If you want access to this report all you need to do is sign up now by clicking the following l...
Source: ACCESSWIRE IA
Date: April, 25 2018 07:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-211.521.5211.571.4843,037
2018-08-201.541.531.541.4530,462
2018-08-141.631.581.681.5178,266
2018-08-131.661.681.69061.6077,645
2018-08-101.561.6351.661.4661,997

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report. Get a complete short report on RXII.


About RXI Pharmaceuticals Corporation (OTC: RXII)

Logo for RXI Pharmaceuticals Corporation (OTC: RXII)

RXi Pharmaceuticals Corporation OTCQX:RXII is a biotechnology company focused on discovering, developing, and commercializing innovative therapies based on its proprietary, next generation RNAi platform. Therapeutics that use RNA interference, or RNAi, have great promise because of their ability to silence or down regulate, the expression of a specific gene that may be expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi s first RNAi product candidate, RXI , entered into RXi s first human trial in . RXI targets connective tissue growth factor CTGF , a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.

 

Contact Information

 

 

Current Management

  • Geert Cauwenbergh / President, CEO
  • Tamara McGrillen / IR
  • Robert J. Bitterman / Chairman
  • Keith L. Brownlie /
  • Geert Cauwenbergh /
  • H. Paul Dorman /
  • Curtis Lockshin /

Current Share Structure

  • Market Cap: $10,142,462 - 03/21/2018
  • Issue and Outstanding: 2,369,734 - 01/08/2018

 


Recent Filings from (OTC: RXII)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 18 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 18 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 13 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 11 2018

 

 


Daily Technical Chart for (OTC: RXII)

Daily Technical Chart for (OTC: RXII)


Stay tuned for daily updates and more on (OTC: RXII)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RXII)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RXII is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of RXII and does not buy, sell, or trade any shares of RXII. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/